Principal Investigator

Patrick VERMERSCH, MD, PhD

University of Lille, CHU of Lille, France

  • 2 trials
  • 1 compound

Therapeutic focus

  • Progressive Multiple Sclerosis
  • Multiple Sclerosis, Secondary Progressive
  • Multiple Sclerosis, Primary Progressive
  • Multiple Sclerosis, Relapse Free

All trials (2)

NCTPhaseStatusCompoundSponsor
NCT05441488Phase 3DiscontinuedMasitinib
NCT01433497Phase 3CompletedMasitinib

Compounds studied

Trial sites (38)

  • Gothenburg, Sweden
  • Bilbao, Spain
  • Saint Petersburg, Russia
  • Katowice, Poland
  • Poissy, France
  • Valencia, Spain
  • Créteil, France
  • Lublin, Poland
  • Sofia, Bulgaria
  • Vinnytsia, Ukraine
  • Nice, France
  • Strasbourg, France
  • Rivne, Ukraine
  • Volos, Greece
  • Thessaloniki, Greece
  • Warsaw, Poland
  • Perm, Russia
  • Madrid, Spain
  • Oświęcim, Poland
  • Poznan, Poland
  • Ksawerów, Poland
  • Ternopil, Ukraine
  • Athens, Greece
  • Marburg, Germany
  • Poitiers, France
  • Rouen, France
  • Lodz, Poland
  • Montpellier, France
  • Larissa, Greece
  • Nîmes, France
  • Lille, France
  • Catania, Italy
  • Moscow, Russia
  • Barcelona, Spain
  • Stockholm, Sweden
  • Campulung Muscel, Romania
  • Toulouse, France
  • Lviv, Ukraine

Investigator and site data mirrored fromClinicalTrials.gov (public domain).